434 related articles for article (PubMed ID: 29204974)
1. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
[TBL] [Abstract][Full Text] [Related]
2. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM
Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
4. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
5. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
[TBL] [Abstract][Full Text] [Related]
6. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
[TBL] [Abstract][Full Text] [Related]
7. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
[No Abstract] [Full Text] [Related]
9. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
[TBL] [Abstract][Full Text] [Related]
10. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound in gout: a useful tool for following urate-lowering therapy.
Ottaviani S; Gill G; Aubrun A; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Jan; 82(1):42-4. PubMed ID: 25543275
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
15. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
Graham GG; Stocker SL; Kannangara DRW; Day RO
Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
18. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR
Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007
[TBL] [Abstract][Full Text] [Related]
19. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare.
Tai V; Gow P; Stewart S; Satpanich P; Li C; Abhishek A; Dalbeth N
Semin Arthritis Rheum; 2024 Apr; 65():152367. PubMed ID: 38215627
[TBL] [Abstract][Full Text] [Related]
20. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]